Comparison of the Area-Under-The-Curve for Vancomycin Estimated Using Compartmental and Non-compartmental Methods in Adult Patients with Normal Renal Function.

AIMS Vancomycin pharmacokinetics are best described using a 2-compartment model. However, 1-compartment population models are commonly used as the basis for dose prediction software. Therefore, the validity of using a 1-compartment model to guide vancomycin drug dosing was examined. METHODS Published plasma concentration-time data from adult subjects (n=30) with stable renal function administered a single intravenous infusion of vancomycin were extracted from previous studies. The vancomycin area-under-the-curve (AUC0-∞) was calculated for each subject using non-compartmental methods (AUCNCA) and by fitting 1- (AUC1CMT), 2- (AUC2CMT), and 3- (AUC3CMT) compartment infusion models. The optimal model fit was determined using the Akaike information criterion and visual inspection of the residual plots. The individual compartmental AUC0-∞ values from the 1- and 2-compartment models were compared with AUCNCA values using one-way repeated measures ANOVA. RESULTS The mean (± standard deviation) AUC estimates were similar for the different methods: AUCNCA 180 ± 86 mg.h/L, AUC1CMT 167 ± 79 mg.h/L, and AUC2CMT 183 ± 88 mg.h/L. Despite the overlapping AUC values, AUC2CMT and AUCNCA were significantly greater than AUC1CMT (P<0.05). The 3-compartment model was excluded from the analysis due to the failure to converge in some instances. CONCLUSIONS Dose prediction software utilizing a 1-compartment model as the basis for Bayesian forecasting underestimates drug exposure (estimated as the AUC) by less than 10%. This is unlikely to be clinically significant with respect to dose adjustment. Therefore, a 1-compartment model may be sufficient to guide vancomycin dosing in adult patients with stable renal function.

[1]  Eric Chang,et al.  Review and Validation of Bayesian Dose‐Optimizing Software and Equations for Calculation of the Vancomycin Area Under the Curve in Critically Ill Patients , 2018, Pharmacotherapy.

[2]  N. Read,et al.  Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus , 2018, Antimicrobial Agents and Chemotherapy.

[3]  A. Schumitzky,et al.  Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing , 2017, Antimicrobial Agents and Chemotherapy.

[4]  M. Barras,et al.  Individualised medicine: why we need Bayesian dosing , 2017, Internal medicine journal.

[5]  Michael N Neely,et al.  Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. , 2014, The Lancet. Infectious diseases.

[6]  S. Zhai,et al.  Benefits of Therapeutic Drug Monitoring of Vancomycin: A Systematic Review and Meta-Analysis , 2013, PloS one.

[7]  Y. Nishi,et al.  Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring , 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[8]  Yong Zhang,et al.  PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel , 2010, Comput. Methods Programs Biomed..

[9]  E. Capparelli,et al.  Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches. , 2010, International journal of clinical pharmacology and therapeutics.

[10]  Tomoyoshi Inoue,et al.  Population Pharmacokinetic Analysis of Vancomycin Using Serum Cystatin C as a Marker of Renal Function , 2009, Antimicrobial Agents and Chemotherapy.

[11]  C. Staatz,et al.  Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. , 2009, The Journal of antimicrobial chemotherapy.

[12]  C. Staatz,et al.  Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery. , 2006, British journal of clinical pharmacology.

[13]  M. J. García,et al.  Population Pharmacokinetic Analysis of Vancomycin in Patients with Hematological Malignancies , 2005, Antimicrobial Agents and Chemotherapy.

[14]  N. Milpied,et al.  Application of USC*PACK clinical programs to vancomycin in neutropenic patients. , 1994, International journal of bio-medical computing.

[15]  R W Jelliffe,et al.  Application of a Bayesian method to monitor and adjust vancomycin dosage regimens , 1990, Antimicrobial Agents and Chemotherapy.

[16]  W. Keane,et al.  Pharmacokinetics of vancomycin in patients with various degrees of renal function , 1984, Antimicrobial Agents and Chemotherapy.

[17]  R. Blouin,et al.  Vancomycin pharmacokinetics in normal and morbidly obese subjects , 1982, Antimicrobial Agents and Chemotherapy.

[18]  D. DuBois,et al.  FIFTH PAPER THE MEASUREMENT OF THE SURFACE AREA OF MAN , 1915 .

[19]  Y. Nishi,et al.  Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring , 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[20]  B. Bruguerolle,et al.  Vancomycin: a review of population pharmacokinetic analyses. , 2012, Clinical pharmacokinetics.

[21]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  D. Levine,et al.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[23]  M. Rybak,et al.  The pharmacokinetic and pharmacodynamic properties of vancomycin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.